STING-targeted PET imaging: unveiling tumor immunogenicity post-chemotherapy in colorectal cancer.
A study published in the European Journal of Nuclear Medicine & Molecular Imaging explores the potential of STING-targeted PET imaging in monitoring tumor immunogenicity in colorectal cancer (CRC) patients after chemotherapy. The study uses a novel PET tracer called [18F]FBTA, which demonstrates hig...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 51; no. 9; pp. 2758 - 2761 |
|---|---|
| Autores principales: | , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jul2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178275943&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178275943 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: Jul2024 vid: 51 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 178275943 177369066 10.1007/s00259-024-06769-9 178275943 ppf: 2758 ppct: 3 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: STING-targeted PET imaging: unveiling tumor immunogenicity post-chemotherapy in colorectal cancer. aug: au: Li, Chao Saladin, Rachel J. Cai, Weibo Chen, Weiyu affil: https://ror.org/03s8txj32 Department of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, China sug: ab: A study published in the European Journal of Nuclear Medicine & Molecular Imaging explores the potential of STING-targeted PET imaging in monitoring tumor immunogenicity in colorectal cancer (CRC) patients after chemotherapy. The study uses a novel PET tracer called [18F]FBTA, which demonstrates higher specificity and sensitivity compared to conventional [18F]FDG. The research findings indicate that [18F]FBTA accurately reflects the impact of different chemotherapeutic agents on the immune activity of CRC tumors. The study suggests that [18F]FBTA holds promise as a reliable clinical tool for guiding treatment decisions and facilitating the combination of immunotherapy with chemotherapy in CRC patients. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|